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Abstract
Background: This study aimed to determine the risk of thromboembolic events in patients with junctional
bradycardia(JB).
Methods: We retrospectively reviewed electrocardiograms(ECGs) for 380,682 patients. Those with JB on an ECG at
least twice over a ≥3-month interval were included for analysis. We additionally included 138 CHADS2 score-
matched patients(age, 68.4 ± 15.7 years; male, 52.2 %) in sinus rhythm as a control group. Between the JB
patients(with or without retrograde P wave) and controls, we compared incidences of ischemic stroke and a
composite of ischemic stroke, renal infarction, ischemic colitis, acute limb ischemia, and pulmonary embolism.
Results: Among 380,682 patients (age, 47.6 ± 19.9 years; male, 49.3 %), 69 patients (age, 68.5 ± 16.5 years; male, 50.7 %)
exhibited JB on an ECG at least twice over a ≥3-month interval; the overall prevalence of JB was 0.02 %. The mean follow-
up period was 27.2 ± 26.2 months. Forty-five patients (65.2 %) in the JB group had no retrograde P wave. Ischemic stroke
incidence was significantly higher in JB patients without a retrograde P wave than in controls (6/45 patients [13.3 %] and
3/138 patients [2.2 %], respectively; P = 0.007). The incidence of composite thromboembolic events was also significantly
higher in JB patients without a retrograde P wave than in controls (8/45 patients [17.8 %] and 4/138 patients [2.9 %],
respectively; P = 0.011). In a Cox proportional hazards model, JB patients without a P wave showed a greater incidence of
stroke (hazard ratio, 8.89 [2.20–33.01], P = 0.007) than controls and JB patients with a P wave.
Conclusions: Junctional bradycardia is potentially associated with ischemic stroke, particularly in the absence of an
identifiable retrograde P wave.
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Background
Junctional bradycardia (JB) involves cardiac rhythms that
arise from the atrioventricular junction at a heart rate of
<60/min. In patients with retrograde atrioventricular
nodal conduction, a retrograde P wave can be accompan-
ied with JB. The event occurs as enhanced automaticity or
as an escape rhythm during significant bradycardia with
rates slower than the intrinsic junctional pacemaker [1].
JB can appear in patients with sick sinus syndrome or
those with significant bradycardia that allows the atrioven-
tricular nodal region to determine the heart rate [2]. As
most of these patients are asymptomatic, there are no
specific guidelines for evaluation and treatment. However,
since there is no physiologic atrial contraction in JB, JB
may be a potential cause of cardioembolic source [3, 4].
Here, we aimed to investigate associations between JB and
thromboembolic events.
Methods
We retrospectively reviewed electrocardiograms (ECGs)
for 380,682 patients (47.6 ± 19.9 years; male, 49.3 %)
from a single university hospital from January 2008 to
December 2012. We screened consecutive patients who
visited our outpatient center or were admitted to our
hospital for ECG recording during the period. We ini-
tially excluded patients who were admitted due to acute
myocardial infarction or acute stroke and patients whose
life expectancy is less than 6 months due to cancer. A
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total of 972,683 ECGs (mean of 2.55 ECGs per patient)
stored in our electronic database system (Muse System,
General Electric Healthcare, Milwaukee, Wisconsin,
USA) were included in this study. Twelve-lead ECGs
were recorded by digital ECG instruments (General
Electric Healthcare, Milwaukee, Wisconsin, USA). The
digital sampling rate was 500 samples per second. The
low and high cut-off frequencies were 0.5 and 100 Hz,
respectively. Initially, the ECGs were screened by an
automated ECG analysis algorithm embedded in our sys-
tem to detect for JB. The algorithm for detecting JB is as
follows: no P wave, a regular RR interval (i.e., an RR
interval range that is less than 10 % of the average RR
interval), narrow primary beat (<0.12 s for QRS dur-
ation), and a regular rate less than 60 beats/min. Then,
three cardiologists reviewed the screened ECGs and
finally selected those exhibiting JB in accordance with
the following: JB was defined as a regular rhythm of less
than 60 beats/min without a precedent P wave and a
narrow QRS complex for a duration of less than 0.12 s.
Retrograde P wave was defined as an inverted P wave
after the QRS complex was noted. Respective ECGs with
JB, with or without a retrograde P wave, were to be
agreed upon by all three cardiologists. Inclusion criteria
for analysis comprised age older than 18 years and JB on
multiple ECGs at an interval of at least 3 months. Patients
with transient JB and those with hyperkalemia at the time
of ECG recording, history of end-stage renal disease, par-
oxysmal atrial fibrillation, and only one recording of JB
were excluded. Additionally, patients who had been
treated with implantation of a pacemaker or cardiac resyn-
chronization therapy due to sick sinus syndrome or
intractable heart failure were excluded from analysis.
Additionally, we also included 138 age-, gender-, and
CHADS2 score-matched patients in sinus rhythm as a
control group; these patients had undergone minor
surgery, including nasal septal deviation and cataract
surgery, in the same period and at the same hospital.
For the controls, we excluded patients with a history of
thromboembolic events, including ischemic stroke, and
those lacking two-dimensional transthoracic echocar-
diographs. Since the incidence of JB was very low we
aimed for 1:2 matching. In addition, to minimize con-
founding factors, we matched age, gender, and CHADS2
score, which are known as risk factors for stroke not only
in patients with atrial fibrillation but also in patients with-
out atrial fibrillation. CHADS2 score was calculated for
each patient by assigning 1 point each for an age ≥75 years,
history of heart failure, hypertension, and diabetes mellitus
and 2 points for previous stroke or transient ischemic
attack. Ischemic stroke was defined as symptomatic ische-
mic cerebral infarction with an apparent brain lesion on
imaging studies. Beginning of follow-up was defined as
time of acquisition of 2nd ECG in JB group and acquisition
of 1st ECG in control group. Transient ischemic attack
(TIA) was defined as a neurologist-confirmed transient
episode of neurologic dysfunction without a brain lesion
on imaging studies. Two-dimensional transthoracic echo-
cardiography was performed using an ultrasound machine
(Vivid 7, GE Medical Systems, Horten, Norway and Sonos
5500, Philips Medical Systems, Andover, Massachusetts,
USA) with a 2.5-MHz transducer. Left atrial volume index
was calculated by the prolate ellipsoid method [5, 6].
Left ventricular ejection fraction was measured using
the modified Simpson’s method [5] on images of apical,
2- and 4-chamber views. Echocardiographic findings
were reviewed by three cardiologists. Clinical character-
istics; medication history; laboratory and imaging data;
and development of ischemic stroke, transient ischemic
attack, renal infarction, ischemic colitis, acute limb
ischemia, and pulmonary embolism were reviewed from
electronic medical records. JB was re-classified into two
groups according to the presence of a retrograde P
wave: JB without a retrograde P wave (JB without P)
group and JB with a retrograde P wave (JB with P)
group. The primary endpoint was ischemic stroke and
transient ischemic attack. The secondary endpoint was
a composite of ischemic stroke, transient ischemic
attack, renal infarction, ischemic colitis, acute limb is-
chemia, and pulmonary embolism. We compared the
incidences of the primary and secondary endpoints
between the JB and control groups, as well as between
the JB without P and JB with P groups. We calculated
hazard ratios of JB for primary and secondary end-
points in comparison to sinus rhythm. We also calcu-
lated hazard ratios of JB without a retrograde P wave
for primary and secondary endpoints in comparison to JB
with a retrograde P wave. The study design was approved
by the Institutional Review Board of Severance Hospital
and conducted in compliance with the Declaration of
Helsinki. The requirement for informed consent was
waived, because of the retrospective nature of the study.
Statistical analysis
Continuous variables are expressed as mean ± standard de-
viation, and categorical variables as numbers (percentages).
Mann-Whitney and Fisher’s exact test were used for com-
parisons of continuous and categorical variables, respect-
ively. Kaplan-Meier curves were constructed for time to
event and compared by log-rank tests confined to 2 years
of follow-up. Univariable and mutivariable Cox propor-
tional hazards models were used to compare hazard ratios
for primary and secondary endpoints between groups. The
log-minus-log-survival function was used to assess the
proportional hazards assumption and found that it was
reasonable. Hazard ratios (HR) and 95 % confidence inter-
vals (CI) were calculated. Two-sided p values <0.05 were
considered statistically significant. The data were analyzed
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using the Statistical Package for the Social Sciences,
version 20.0 (IBM Inc., Armonk, NY, USA).
Results
Population
The overall prevalence of JB for all 380,682 patients
screened was 0.02 % in the present study. In total, 75
patients showed JB on ECGs twice over an interval of at
least 3 months. Two patients had undergone implant-
ation of pacemaker device and were excluded from ana-
lysis. An additional 4 patients who underwent cardiac
surgery were excluded due to anticoagulation therapy
that was maintained after valve surgery and clinical
events that occurred during the immediate post-
operative period. Finally, we included 69 patients
(age, 68.5 ± 16.5 years; male, 50.7 %) with JB on
ECGs. Among these, 40 patients (58 %) had been
admitted; 29 patients (73 %) were admitted due to
cardiovascular disease (14 patients with coronary ar-
tery disease, 7 patients with valvular heart disease,
and 7 patients with myocardial disease). Of the 69
patients, three (4.3 %) had symptoms that might be
associated with JB: two complained of orthostatic
dizziness at an outpatient center. Their ECG revealed
JB without a retrograde P wave. The other patient
had a history of syncope, assumedly vasovagal syn-
cope, and her ECG revealed JB with a retrograde P
wave. These patients, however, did not receive any
specific treatment, including pacemaker implantation.
We also included 138 age-, gender-, and CHADS2
score-matched patients (age, 68.4 ± 15.7 years; male,
52.2 %) as a control group. Baseline characteristics
for both groups are presented in Table 1. Thirty pa-
tients (43.5 %) underwent Holter monitoring and had
no evidence of atrial fibrillation. The patients in the
JB and control groups were followed for 27.2 ±
26.2 months and 25.4 ± 21.5 months, respectively, and
44.9 % of the patients had a CHADS2 score ≥2.
Chronic kidney disease was significantly more frequent in
the JB group than in the control group (P = 0.042). Left
atrial volume index was significantly greater in the JB
group than in the control group (P = 0.001). There were
no significant differences in age, sex, comorbidities (hyper-
tension, diabetes, heart failure, coronary artery disease,
and stroke) or ejection fraction between the JB and
control groups.





P value* JB with P group
(n = 24)
JB without P group
(n = 45)
P value**
Age (years) 68.5 ± 16.5 68.4 ± 15.7 0.593 67.3 ± 16.6 69.2 ± 16.5 0.273
Men, n (%) 35 (50.7) 72 (52.2) 0.883 10 (41.7) 25 (55.6) 0.318
Smoking, n (%) 26 (37.7) 40 (29.0) 0.210 8 (33.3) 18 (40.0) 0.614
Hypertension, n (%) 39 (56.5) 76 (55.1) 0.883 11 (45.8) 28 (62.2) 0.213
Diabetes mellitus, n (%) 30 (43.5) 50 (36.2) 0.364 8 (33.3) 22 (48.9) 0.308
Heart failure, n (%) 6 (8.7) 11 (8.0) >0.999 3 (12.5) 3 (6.7) 0.412
Chronic kidney disease, n (%) 20 (29.0) 22 (15.9) 0.043 5 (20.8) 15 (33.3) 0.404
History of CAD, n (%) 21 (30.4) 44 (31.9) 0.875 3 (12.5) 18 (40.0) 0.027
History of stroke, n (%) 1 (1.4) 1 (0.7) >0.999 0 (0.0) 1 (2.2) >0.999
Ejection fraction (%) 64.2 ± 11.3 63.3 ± 11.0 0.485 63.8 ± 13.4 64.4 ± 10.1 0.772
LAVI (ml/m2) 45.1 ± 30.3 28.0 ± 11.3 0.001 40.8 ± 10.4 47.1 ± 36.1 0.740
Antiplatelet agents, n (%) 33 (47.8) 101 (73.2) 0.883 9 (37.5) 24 (53.3) 0.312
Statin, n (%) 26 (37.7) 52 (37.7) >0.999 7 (29.2) 19 (42.2) 0.312
Anticoagulants, n (%) 8 (11.6) 6 (4.3) 0.091 2 (8.3) 6 (13.3) 0.704
CHADS2 score 1.48 ± 1.16 1.49 ± 1.19 0.991 1.17 ± 1.13 1.64 ± 1.15 0.103
0, n (%) 16 (23.2) 32 (23.2) 8 (33.3) 8 (17.8)
1, n (%) 22 (31.9) 44 (31.9) 8 (33.3) 14 (31.1)
2, n (%) 16 (23.2) 32 (23.2) 5 (20.8) 11 (24.4)
3, n (%) 12 (17.4) 24 (17.4) 2 (8.3) 10 (22.2)
4, n (%) 3 (4.3) 6 (4.3) 1 (4.2) 2 (4.4))
Follow-up duration (month) 27.2 ± 26.2 25.4 ± 21.5 0.948 39.3 ± 36.5 20.7 ± 15.6 0.008
CAD coronary artery disease, JB junctional bradycardia, LAVI left atrial volume index
*comparison between the JB group and control group
**comparison between the JB without P group and JB with P group
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Thromboembolic events
Incidences of thromboembolic events are summarized
in Table 2. Thromboembolic events occurred in 8
patients (17.8 %) in the JB without P group. In contrast,
thromboembolic events occurred in one (4.2 %) and 4
(2.9 %) patients in the JB with P group and the control
group, respectively. Stroke and composite thrombo-
embolic events were significantly more frequent in the
JB without P group than the control and JB with P
groups. Six patients (13.3 %) developed stroke in the JB
without P group, and the time interval between detec-
tion of JB and the date the events occurred ranged from
1 month to 4 years. Among 6 patients, three had under-
gone cardiac surgery (coronary artery bypass graft in 2
patients and mitral valve repair in 1 patient). Their
clinical events occurred 40 months, 31 months, and
7 months after cardiac surgery. We summarized the
clinical history of patients who showed thrombo-
embolic events in Table 3. We could not compare the
incidences of renal infarction, ischemic colitis, acute
limb ischemia, and pulmonary embolism due to their
rare incidence. Using the Cox proportional hazards
model, JB without retrograde P wave was significantly
associated with both stroke and composite thrombo-
embolic events, even after adjusting for confounding
clinical factors, such as gender and CHADS2 score,
as described on Table 4. After excluding TIA, JB
without retrograde P wave was also associated with
incidence of stroke in multivariable analysis, which
included gender and CHADS2 score (hazard ratio, 5.062
[2.12–22.63], P = 0.034).
We compared the incidence of stroke or transient
ischemic attack among the three groups using Kaplan-
Meier curves over 48 months of follow-up, as shown in
Fig. 1. A difference in event-free survival was noted in
the early period of follow-up and did not decrease after
follow-up for up to 48 months.
Discussion
In the present study, JB was found to be potentially associ-
ated with the occurrence of a composite of thrombo-
embolic events. JB without a retrograde P wave was also
shown to be a significant risk factor for both the occurrence
of stroke and the composite of thromboembolic events.
Paroxysmal atrial fibrillation and sick sinus syndrome
have been reported as risk factors for thromboembolic
events, such as acute stroke [4, 7–9]. Paroxysmal atrial
fibrillation is considered an earlier form of arrhythmia,
showing less electrical and structural remodeling of the
atria; nonetheless, the risk of thromboembolic events is
similar for persistent or permanent atrial fibrillation.
Accordingly, most current guidelines recommend the use
of oral anticoagulation for patients with stroke risk factors,
irrespective of the type of atrial fibrillation [10, 11]. Sinus
node dysfunction is also reported as a risk factor for stroke
[3, 12]. The annual incidence of stroke in patients with sick
sinus syndrome is estimated at approximately 6–10 %, even
after pacemaker implantation and physiologic pacing, such
as DDD mode [4, 9, 13]. Virchow described a triad of ab-
normalities associated with thrombus formation: abnormal
vessel wall, abnormal blood constituents, and abnormal
flow [14]. Of these, ineffective atrial contraction could be
associated with abnormal flow. Atrial performance is
categorized into four phases: reservoir function, conduit
function, active contractile pump function, and suction
force [15]. In late diastole, the atrium behaves as a pump
as pressure rises due to active atrial contraction and pushes
the blood through the mitral valve, contributing 15–30 %
to left ventricular filling [16, 17]. In a case report of
thromboembolism in a patient with intermittent periods of
sinus arrest and junctional escape bradycardia, spontan-
eous echo contrast was detected on transthoracic echocar-
diography [13]. Additionally, Vincelj et al. reported that
spontaneous echo contrast is associated with left atrial
enlargement, which is known as a risk factor for thrombo-
embolism [18]. Thus, spontaneous echo contrast suggested
that inactive atrial pumping might cause blood stagnation
and could be associated with cardioembolic embolism.
We hypothesized that JB would show similar patho-
physiology to atrial fibrillation and sick sinus syndrome
in terms of ineffective atrial contraction, which may be a
cardiogenic thromboembolic source. Our data indicated
that JB without retrograde P wave is a robust risk factor
for both stroke and thromboembolic events in multivari-
able analysis. However, the main pathogenic mechanism










P value P value
Stroke (%) 0 4 (8.9) 3 (2.2) –
TIA (%) 0 2 (4.4) 0
Stroke and
TIA (%)
0 6 (13.3) 3 (2.2) 0.007*
Renal infarction,
n (%)
1 (4.2) 0 0 – –
Ischemic colitis,
n (%)
0 0 1 (0.7) – –
Acute limb
ischemia, n (%)
0 1 (2.2) 0 – –
Pulmonary
embolism, n (%)




1 (4.2) 8 (17.8) 4 (2.9) 0.011** 0.059***
JB junctional bradycardiaTIA transient ischemic attack
*comparison between the JB without P group and control group
**comparison among the JB without P group, JB with P group, and control group
***comparison between the JB without P group and JB with P group
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for thromboembolic events is not well understood. In 3
patients who experienced thromboembolic events in the
JB without P group, thromboembolic events did not
occur in the immediate postoperative period. Therefore,
the events could not be complications associated with
cardiac surgery.
Additionally, in the present study, left atrial volume
index (LAVI) was significantly larger in the JB group
(45 ml/m2 vs. 28 ml/m2) than in the control group. The
left atrium is highly susceptible to acute and chronic stress
factors, such as alterations in both preload and afterload
[19]. Reportedly, left atrial volume index is a more accur-
ate parameter for left atrial size than left atrial diameter.
Previously, Corbalan et al. reported that left atrial enlarge-
ment on two-dimensional echocardiography is a signifi-
cant independent risk factor for systemic embolism in
patients with symptomatic paroxysmal atrial fibrillation
[20]. In addition to patients with atrial fibrillation, LAVI
has also been shown to be associated with stroke and
cardiac thrombi in patients with sinus rhythm or without
Table 3 Clinical information in patients with thromboembolic events
Patients number Age Sex Group Heart rate
(/min)
Thromboembolic events Underlying disease
1 74 Female Control 70 Stroke HTN, CAD
2 74 Female Control 66 Stroke HTN, DM
3 80 Male Control 80 Ischemic colitis HTN, DM
4 79 Male Control 56 Stroke HTN, DM, CAD
5 65 Female JB with P 40 Renal infarction HTN
6 66 Female JB without P 40 TIA none
7 73 Male JB without P 46 PAD HTN, CAD (s/p CABG)
8 80 Male JB without P 50 Pulmonary embolism HTN, DM, CKD, CAD (s/p CABG)
9 70 Male JB without P 48 Stroke HTN, DM, s/p MVR
10 86 Male JB without P 50 TIA HTN
11 80 Male JB without P 52 Stroke HTN, DM, CKD (s/p kidney transplantation), CAD
12 78 Female JB without P 56 Stroke HTN, DM, CAD
13 88 Female JB without P 46 Stroke HTN, DM, CKD, CAD
CABG coronary artery bypass graft surgery, CAD coronary artery disease, CKD chronic kidney disease, DM diabetes mellitus, HTN hypertension, JB junctional
bradycardia, LAD left anterior descending, MVR mitral valve repair, P P wave, PAD peripheral artery disease, SCD sudden cardiac death, TIA transient ischemic attack
Table 4 Independent predictors of thromboembolic events
Univariable Mutivariable
HR (95 % CI) P value HR (95 % CI) P value
a. Stroke and transient ischemic attack
Male 0.58 (0.14–2.34) 0.472
Chronic kidney disease 1.95 (0.48–7.82) 0.352
CHADS2 score ≥2 5.74 (1.17–28.25) 0.032 4.67 (0.96–22.73) 0.062
***
LAVI (ml/m2) 1.01 (0.97–1.06) 0.562
JB* 2.60 (0.59–11.53) 0.210
JB without P** 6.56 (1.61–26.75) 0.007 8.89 (2.20–33.01) 0.002***
b. Composite thromboembolic events
Male 0.99 (0.36–3.27) 0.993
Chronic kidney disease 1.75 (0.54–5.70) 0.352
CHADS2 score ≥2 3.44 (1.04–11.33) 0.043 4.07 (1.11–14.87) 0.031
***
LAVI (ml/m2) 1.01 (0.99–1.03) 0.391
JB without P** 5.69 (1.84–17.63) 0.003 5.04 (1.68–15.09) 0.004***
JB junctional bradycardia, LAVI left atrial volume index, P P wave
*comparison with the control group
**comparison with the control group and JB with P group
***adjustment for male sex, CHADS2 score ≥2, and JB without P group
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atrial fibrillation [21, 22]. Thus, in the JB group, large left
atrial volume index could be associated with loss of atrial
kick, which might contribute to increased preload of the
left atrium.
We used the CHADS2 scoring system to control for
confounding factors in predicting the risk of stroke
based on junctional rhythm, since the CHADS2 scheme
has been reported as a reliable predictive parameter in
patients without atrial fibrillation [23, 24]. CHADS2
score did not predict stroke or thromboembolic events
even in subgroup analysis (JB without retrograde P
wave), unlike previous reports in which CHADS2 and
CHA2DS2-VASc scores were associated with an in-
creased risk of stroke in patients with paced sick sinus
syndrome [7]. This difference between results could be
explained by variation in the study populations.
When patients with JB have co-morbidities that are
known risk factors for embolic events, preventive strat-
egies, such as anticoagulant administration or pacemaker
implantation, might be considered. However, a random-
ized controlled study with a large population is also
needed to confirm these findings.
Limitations
There are some limitations to our study. First, it is a
retrospective study of a relatively small sample size
conducted in a single center. Furthermore, continuous
ECG monitoring, such as Holter monitoring, was only
performed in about 43 % of the patients with JB; there-
fore, we could not guarantee the absence of asymptom-
atic paroxysmal atrial fibrillation in patients without
Holter monitoring. Furthermore, because of the very low
prevalence of JB and very small number of clinical
events, it would be difficult to conclude a robust correl-
ation between JB and clinical events such as stroke.
Thus, a large-scale, prospective, observational study is
being contemplated.
Conclusions
Junctional bradycardia is potentially associated with is-
chemic stroke, particularly in the absence of an identifi-
able retrograde P wave.
Abbreviations
CI, confidence interval; ECG, electrocardiogram; HR, heart rate; JB with P,
junctional bradycardia with P wave; JB without P, junctional bradycardia
without P wave; JB, junctional bradycardia; LAVI, left atrial volume index; TIA,
transient ischemic attack
Acknowledgements
The authors thank Jinae Lee, PhD, and Jung Hwa Hong, MS, from the
Biostatistics Collaboration Unit, Yonsei University College of Medicine, for
their help with the statistical analyses.
Funding
No funding was obtained in this study.
Availability of data and materials
All the data supporting our findings is contained within the manuscript.
Fig. 1 Kaplan-Meier curve of the incidence of stroke at 48 months follow-up after the detection of junctional bradycardia. JB = junctional bradycardia;
P = P wave; TIA = transient ischemic attack
Kim et al. BMC Neurology  (2016) 16:113 Page 6 of 7
Authors’ contributions
GSK and JSU were involved in the study design, interpretation of data,
drafting and revising of the manuscript. THK, HCL and JBP were participated
in data collection, statistical analysis and interpretation of data. JKP and BYJ
were involved in the study concept and design. HNP and MHL were
involved in the supervision and coordination of the study and revised the
manuscript for content. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study design was approved by the Institutional Review Board of
Severance Hospital (4-2016-0350) and conducted in compliance with the
Declaration of Helsinki. The requirement for informed consent was waived,
because of the retrospective nature of the study.
Received: 19 November 2015 Accepted: 22 July 2016
References
1. Josephson M. Clinical Cardiac Electrophysiology. 4th ed. Philadelphia:
Lippincott Williams and Wilkins; 2008.
2. Libby P, Bonow R, Mann D, Zipes. Specific arrhythmias: diagnosis and
treatment. In: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia:
Saunders; 2007. p. 640–5.
3. Fairfax AJ, Lambert CD, Leatham A. Systemic embolism in chronic sinoatrial
disorder. N Engl J Med. 1976;295:190–2.
4. Fisher M, Kase CS, Stelle B, Mills RM. Ischemic stroke after cardiac pacemaker
implantation in sick sinus syndrome. Stroke. 1988;19:712–5.
5. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA,
Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT,
Sutton MS, Stewart WJ, Chamber Quantification Writing G, American Society
of Echocardiography's G, Standards C, European Association of E.
Recommendations for chamber quantification: a report from the American
Society of Echocardiography's Guidelines and Standards Committee and the
Chamber Quantification Writing Group, developed in conjunction with the
European Association of Echocardiography, a branch of the European
Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.
6. Ujino K, Barnes ME, Cha SS, Langins AP, Bailey KR, Seward JB, Tsang TS.
Two-dimensional echocardiographic methods for assessment of left atrial
volume. Am J Cardiol. 2006;98:1185–8.
7. Svendsen JH, Nielsen JC, Darkner S, Jensen GV, Mortensen LS, Andersen HR,
Investigators D. CHADS2 and CHA2DS2-VASc score to assess risk of stroke
and death in patients paced for sick sinus syndrome. Heart. 2013;99:843–8.
8. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S,
Connolly SJ, Investigators AW. Incidence of stroke in paroxysmal versus
sustained atrial fibrillation in patients taking oral anticoagulation or
combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll
Cardiol. 2007;50:2156–61.
9. Greenspon AJ, Hart RG, Dawson D, Hellkamp AS, Silver M, Flaker GC, Schron
E, Goldman L, Lee KL, Lamas GA, Investigators MS. Predictors of stroke in
patients paced for sick sinus syndrome. J Am Coll Cardiol. 2004;43:1617–22.
10. Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM,
January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster
V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le
Heuzey J, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS.
Management of patients with atrial fibrillation (compilation of 2006 ACCF/
AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the
American College of Cardiology/American Heart Association Task Force on
practice guidelines. Circulation. 2013;127:1916–26.
11. Saksena S, Camm AJ, Boyden P, Dorian P, Goldschlager N.
Electrophysiological disorders of the heart. Philadelphia: Churchill
Livingstone; 2005.
12. Alonso A, Jensen PN, Lopez FL, Chen LY, Psaty BM, Folsom AR, Heckbert SR.
Association of sick sinus syndrome with incident cardiovascular disease and
mortality: the atherosclerosis risk in communities study and cardiovascular
health study. PLoS One. 2014;9:e109662.
13. Koller-Strametz J, Wieselthaler G, Kratochwill C, Laufer G, Pacher R, Heinz G.
Thromboembolism associated with junctional escape rhythm and atrial
standstill after orthotopic heart transplantation. J Heart Lung Transplant.
1995;14:999–1002.
14. Bennett PC, Silverman SH, Gill PS, Lip GYH. Peripheral arterial disease and
Virchow's triad. ThrombHaemost. 2009;101:1032-40.
15. Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G,
Galderisi M, Marwick T, Nagueh SF, Sengupta PP, Sicari R, Smiseth OA,
Smulevitz B, Takeuchi M, Thomas JD, Vannan M, Voigt JU, Zamorano JL.
Current and evolving echocardiographic techniques for the quantitative
evaluation of cardiac mechanics: ASE/EAE consensus statement on
methodology and indications endorsed by the Japanese Society of
Echocardiography. Eur J Echocardiogr. 2011;12:167–205.
16. Appleton CP, Hatle LK, Popp RL. Relation of transmitral flow velocity
patterns to left ventricular diastolic function: new insights from a combined
hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol.
1988;12:426–40.
17. Pagel PS, Kehl F, Gare M, Hettrick DA, Kersten JR, Warltier DC.
Mechanical function of the left atrium: new insights based on analysis
of pressure-volume relations and Doppler echocardiography.
Anesthesiology. 2003;98:975–94.
18. Vincelj J, Sokol I, Jaksic O. Prevalence and clinical significance of left atrial
spontaneous echo contrast detected by transesophageal echocardiography.
Echocardiography. 2002;19:319–24.
19. Pavlopoulos H, Nihoyannopoulos P. Left atrial size: a structural expression of
abnormal left ventricular segmental relaxation evaluated by strain
echocardiography. Eur J Echocardiogr. 2009;10:865–71.
20. Corbalan R, Arriagada D, Braun S, Tapia J, Huete I, Kramer A, Chavez A. Risk
factors for systemic embolism in patients with paroxysmal atrial fibrillation.
Am Heart J. 1992;124:149–53.
21. Gagne Brosseau MS, Boulanger JM, Leblanc N, Berger L, Benzazon M. Left
atrium dilatation and multiple vascular territory strokes. Can J Neurol Sci.
2014;41:704–8.
22. Bakalli A, Georgievska-Ismail L, Kocinaj D, Musliu N, Krasniqi A, Pllana E.
Prevalence of left chamber cardiac thrombi in patients with dilated left
ventricle at sinus rhythm: the role of transesophageal echocardiography.
J Clin Ultrasound. 2013;41:38–45.
23. Lip GY, Lin HJ, Chien KL, Hsu HC, Su TC, Chen MF, Lee YT. Comparative
assessment of published atrial fibrillation stroke risk stratification schemes
for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan
Community Cohort Study. Int J Cardiol. 2013;168:414–9.
24. Ntaios G, Lip GY, Makaritsis K, Papavasileiou V, Vemmou A, Koroboki E,
Savvari P, Manios E, Milionis H, Vemmos K. CHADS(2), CHA(2)S(2)DS(2)-VASc,
and long-term stroke outcome in patients without atrial fibrillation.
Neurology. 2013;80:1009–17.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kim et al. BMC Neurology  (2016) 16:113 Page 7 of 7
